TCM
MRSN

Tekla Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Tekla Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,495
Closed -$667K – 176
2023
Q1 		$667K Buy
+6,495
New +$912K 0.03% 140

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Tekla Capital Management's MRSN Position: Q2 2023 in Review

Tekla Capital Management sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 6,495 shares — an estimated $667K sold.

Tekla Capital Management first reported a position in MRSN in Q1 2023 and held it in 1 quarter. The position peaked at $667K in Q1 2023. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Tekla Capital Management reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Tekla Capital Management sold 6,495 Mersana Therapeutics shares in Q2 2023, an estimated $667K.
  • Tekla Capital Management first reported a position in Mersana Therapeutics in Q1 2023 and held it in 1 quarter.
  • Tekla Capital Management's Mersana Therapeutics position peaked at $667K in Q1 2023.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.